KROS
Keros Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$10.64+0.28%
Price as of Jul 17, 2026
KROS ownership
Keros Therapeutics, Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
26/100
Buys (3m)
3
Sells (3m)
4
Net (3m)
-$58.6K
Insiders buying
Insider trades by month Buys Sells
Feb
Mar
Apr
May
Jun
Jul
Context3-month price -8.7%Institutions reducing (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 17, 2026 | BIENAIME JEAN JACQUESdirector | Buy | 1,000 | $10.61 |
| Jul 6, 2026 | Prener Annedirector | Grant | 14,870 | $10.88 |
| Jul 6, 2026 | Prener Annedirector | Grant | 13,786 | — |
| Jun 17, 2026 | BIENAIME JEAN JACQUESdirector | Buy | 1,000 | $10.19 |
| Jun 15, 2026 | Newton Charles W.director | Sell | 550 | $10.04 |
| Jun 8, 2026 | Farzan Nimadirector | Sell | 2,625 | $10.73 |
| Jun 8, 2026 | Knowles Juliusdirector | Sell | 2,625 | $10.73 |
| Jun 5, 2026 | BIENAIME JEAN JACQUESdirector | Grant | 7,142 | — |
| Jun 5, 2026 | Farzan Nimadirector | Grant | 7,433 | $10.50 |
| Jun 5, 2026 | GRAY MARY ANNdirector | Grant | 7,142 | — |
| Jun 5, 2026 | Seth Alpnadirector | Grant | 7,142 | — |
| Jun 5, 2026 | GRAY MARY ANNdirector | Grant | 7,433 | $10.50 |
| Jun 5, 2026 | BIENAIME JEAN JACQUESdirector | Grant | 7,433 | $10.50 |
| Jun 5, 2026 | Seth Alpnadirector | Grant | 7,433 | $10.50 |
| Jun 5, 2026 | Seth Alpnadirector | Sell | 2,625 | $10.72 |
| Jun 5, 2026 | Knowles Juliusdirector | Grant | 7,142 | — |
| Jun 5, 2026 | Knowles Juliusdirector | Grant | 7,433 | $10.50 |
| Jun 5, 2026 | Farzan Nimadirector | Grant | 7,142 | — |
| May 19, 2026 | BIENAIME JEAN JACQUESdirector | Buy | 1,000 | $10.58 |
| Apr 17, 2026 | BIENAIME JEAN JACQUESdirector | Buy | 1,000 | $11.70 |
| Apr 6, 2026 | Seehra Jasbirdirector, officer: CHIEF EXECUTIVE OFFICER | Option | 55,000 | $0.30 |
| Mar 27, 2026 | Cho Estherofficer: Chief Legal Officer | Grant | 80,000 | $15.52 |
| Mar 11, 2026 | BIENAIME JEAN JACQUESdirector | Buy | 2,000 | $11.21 |
| Mar 11, 2026 | Newton Charles W.director | Grant | 14,788 | $11.35 |
| Mar 11, 2026 | Newton Charles W.director | Grant | 13,215 | — |
| Feb 26, 2026 | Seehra Jasbirdirector, officer: CHIEF EXECUTIVE OFFICER | Grant | 100,000 | $15.52 |
| Feb 26, 2026 | Regnante Keithofficer: CHIEF FINANCIAL OFFICER | Grant | 60,000 | $15.52 |
| Feb 26, 2026 | Seehra Jasbirdirector, officer: CHIEF EXECUTIVE OFFICER | Grant | 217,000 | $15.52 |
| Feb 20, 2026 | Cho Estherofficer: SVP, General Counsel | Sell | 4,745 | $16.35 |
| Feb 20, 2026 | Lerner Lorena Raquelofficer: Chief Science Officer | Sell | 3,873 | $16.35 |
Source: KROS SEC Form 4 filings, latest Jul 17, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their KROS positions over the last 6 months (SEC Form 13F).
Increased
92
New positions
64
Reduced
125
Sold out
78
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| BLACKROCK, INC. | Increased | 2.4M | May 13, 2026 |
| BLACKROCK, INC. | Reduced | 2.3M | Feb 12, 2026 |
| VANGUARD GROUP INC | Reduced | 1.5M | Jan 29, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Increased | 1.4M | May 15, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | Increased | 1.3M | Feb 13, 2026 |
| STATE STREET CORP | Reduced | 1.1M | Feb 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 831K | May 15, 2026 |
| MADISON AVENUE PARTNERS, LP | Reduced | 824K | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 804K | Feb 17, 2026 |
| QUBE RESEARCH & TECHNOLOGIES LTD | Increased | 784K | Feb 17, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | Increased | 768K | Feb 13, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 759K | May 15, 2026 |
| D. E. SHAW & CO., INC. | Reduced | 755K | Feb 17, 2026 |
| QUBE RESEARCH & TECHNOLOGIES LTD | Reduced | 725K | May 15, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | Reduced | 706K | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.